Back to search results

Observational Study of Viral-Associated Cancers and Immune Disorders

This is an observational study looking at cancers linked to viruses, cancers in people with HIV or other immune problems, and Castleman disease. Researchers want to understand the biology of these cancers better. They will collect tissue samples to study the genes (genome) and other factors that might cause or affect these diseases. This information could help find new ways to prevent, detect, and treat cancer. You might be able to join if you are an adult (18 or older) with HIV or another immune disorder and cancer, a cancer thought to be caused by a virus, or certain cancers that are common in people with HIV, like Kaposi's Sarcoma or Multicentric Castleman Disease. The main goal is to collect high-quality tissue samples for molecular research.

Study design
This is an observational study, meaning no specific treatments are being tested. It aims to enroll 280 participants.
What's involved
You will be screened with a medical history, physical exam, and lab tests. Tissue samples will be collected at the time of collection.
Compensation
Not stated in the trial record.
Follow-up
Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03300830

Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease

Recruiting
Not specifiedAges 18+Observational
National Cancer Institute (NCI)
~280 participants
Updated 2026-08-24 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Tissue collection
Measured over Time of collection

Conditions

Human Immunodeficiency Virus
Castleman's Disease
Kaposi's Sarcoma
Viral-Associated Cancer

Explore related trials

Castleman DiseaseHIV InfectionImmunodeficiencyKaposi SarcomaViral-Associated Cancer

Where it's being run

1 sites across 1 states
Maryland1

Study leadership

  • Robert Yarchoan, M.D. · PRINCIPAL_INVESTIGATOR · National Cancer Institute (NCI)

Who to contact

Irene B Ekwede, R.N.
[email protected]
(240) 760-6126
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

HIV or other acquired immunodeficiency and cancer
Viral-associated cancer or cancer hypothesized to be caused by a virus
HIV-negative participants with cancer that commonly occurs in people with HIV
KSHV-associated malignancy or related diseases, such as Multicentric Castleman Disease (MCD)
A malignancy hypothesized to be caused by an endogenous retrovirus
Idiopathic Castleman disease
Age \>=18 years.
ECOG performance status \<=2 (Karnofsky \>=60%) if biopsy to be performed is solely for the purposes of this protocol. Any ECOG performance status will be allowed if biopsy required for participant care or another NIH protocol that allows lower performance status or if enrollment on this protocol is only for the purposes of studying tissue that has already been collected.
Participants must have signed or be willing to sign an IRB-approved informed consent document that permits the use of the tumor and other samples for genomic-based molecular characterization projects. Telephone consent for use of archival tissue or tissue collected on another protocol or standard participant care will be permitted.
Co-enrollment on other HAMB, NCI, or NIH protocols is allowed

Exclusion

Inability to provide informed consent.
Pregnancy: Pregnant women will not be allowed to participate in this study because there is not a potential benefit.

What this trial measures

  • Tissue collectionTime of collection

    Molecular data from viral associated malignancies, malignancies occurring in the setting of HIV or other immunodeficiencies, and Castleman disease